|
1
|
Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease.
|
Drugs
|
2005
|
1.33
|
|
2
|
Sex differences in the association of apolipoprotein E and angiotensin-converting enzyme gene polymorphisms with healthy aging and longevity: a population-based study from Southern Italy.
|
J Gerontol A Biol Sci Med Sci
|
2006
|
0.97
|
|
3
|
Neuropsychiatric symptoms and functional status in Alzheimer's disease and vascular dementia patients.
|
Curr Alzheimer Res
|
2012
|
0.89
|
|
4
|
APOE epsilon 2/epsilon 4 genotype a risk factor for primary progressive aphasia in women.
|
Arch Neurol
|
2009
|
0.88
|
|
5
|
Genotypes and haplotypes in the IL-1 gene cluster: analysis of two genetically and diagnostically distinct groups of Alzheimer patients.
|
Neurobiol Aging
|
2005
|
0.84
|
|
6
|
Methylenetetrahydrofolate reductase and angiotensin converting enzyme gene polymorphisms in two genetically and diagnostically distinct cohort of Alzheimer patients.
|
Neurobiol Aging
|
2003
|
0.84
|
|
7
|
Epithelial-smooth muscle cooperation is needed for brain natriuretic peptide-dependent bronchorelaxant activity.
|
Pulm Pharmacol Ther
|
2012
|
0.83
|
|
8
|
Novel bronchodilators in asthma.
|
Curr Opin Pulm Med
|
2010
|
0.83
|
|
9
|
Preclinical evaluation of an inhibitor of cytosolic phospholipase A2α for the treatment of asthma.
|
J Pharmacol Exp Ther
|
2011
|
0.83
|
|
10
|
Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease.
|
Expert Opin Ther Targets
|
2007
|
0.82
|
|
11
|
Apoe epsilon2-epsilon4 genotype is a possible risk factor for primary progressive aphasia.
|
Ann Neurol
|
2006
|
0.81
|
|
12
|
Immunomodulatory impact of a synbiotic in T(h)1 and T(h)2 models of infection.
|
Ther Adv Respir Dis
|
2010
|
0.80
|
|
13
|
Survival in Alzheimer's disease is shorter in women carrying heterozygosity at codon 129 of the PRNP gene and no APOE epsilon 4 allele.
|
Dement Geriatr Cogn Disord
|
2008
|
0.80
|
|
14
|
Roflumilast in chronic obstructive pulmonary disease: evidence from large trials.
|
Expert Opin Pharmacother
|
2010
|
0.80
|
|
15
|
Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination.
|
Pulm Pharmacol Ther
|
2006
|
0.79
|
|
16
|
Energy expenditure and impact of bronchodilators in COPD patients.
|
Respir Med
|
2010
|
0.78
|
|
17
|
Pharmacological characterization of adenosine receptors on isolated human bronchi.
|
Am J Respir Cell Mol Biol
|
2011
|
0.78
|
|
18
|
Angiotensin-converting enzyme (ACE) genotypes and disability in hospitalized older patients.
|
Age (Dordr)
|
2010
|
0.77
|
|
19
|
Arformoterol tartrate in the treatment of COPD.
|
Expert Rev Respir Med
|
2010
|
0.77
|
|
20
|
Novel approaches to the treatment of pneumonia.
|
Trends Pharmacol Sci
|
2003
|
0.76
|
|
21
|
Association of apolipoprotein E and angiotensin converting enzyme gene polymorphisms with the multidimensional impairment in older patients.
|
Rejuvenation Res
|
2009
|
0.76
|
|
22
|
Delivering antibacterials to the lungs: considerations for optimizing outcomes.
|
Am J Respir Med
|
2002
|
0.76
|
|
23
|
Lack of association between genetic variants in the mannose-binding lectin 2 (MBL2) gene and HPV infection.
|
Eur J Epidemiol
|
2007
|
0.75
|